Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

RxSight Q2 Adj. EPS $(0.08) Beats $(0.17) Estimate, Sales $33.64M Miss $39.77M Estimate

Author: Benzinga Newsdesk | August 07, 2025 03:06pm
RxSight (NASDAQ:RXST) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.17) by 52.94 percent. The company reported quarterly sales of $33.64 million which missed the analyst consensus estimate of $39.77 million by 15.43 percent. This is a 3.58 percent decrease over sales of $34.89 million the same period last year.

Posted In: RXST


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist